Innate Pharma (IPHA) Liabilities and Shareholders Equity (2017 - 2025)

Innate Pharma (IPHA) has reported Liabilities and Shareholders Equity for 9 consecutive years, with $71.4 million the latest figure, recorded in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 43.53% year-over-year to $71.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $475.9 million (down 34.33% YoY) and the FY2025 annual result came in at $71.4 million, down 43.53% from the prior year.
• Liabilities and Shareholders Equity retreated to $71.4 million in Q4 2025 per IPHA's latest filing, from $105.8 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for IPHA reached as high as $319.1 million in Q2 2022 and fell as low as $71.4 million in Q4 2025.
• A 5-year average of $205.5 million and a median of $212.9 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity tumbled 99.91% — and 2022, when it grew 5.34%.
• Year by year, Liabilities and Shareholders Equity stood at $304.4 million in 2021, then dropped by 25.5% to $226.8 million in 2022, then slipped by 12.1% to $199.4 million in 2023, then tumbled by 36.61% to $126.4 million in 2024, then sank by 43.53% to $71.4 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $71.4 million, $105.8 million, and $126.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.